Benefit of Pembrolizumab/Axitinib Combo in Intermediate/Poor-Risk RCC

Pembrolizumab plus axitinib significantly improved overall survival, progression-free survival, and response rate as first-line treatment compared with sunitinib in patients with metastatic renal cell carcinoma (RCC) with intermediate/poor risk disease and those with sarcomatoid features, according to results of the KEYNOTE-426 study (abstract 4500) presented at the 2019 American Society of Clinical Oncology (ASCO)

Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news